Highlight
1. Dose reductions and discontinuations of antifibrotic medications nintedanib and pirfenidone are common in clinical practice due to poor tolerability in patients with IPF.
2. Real-world data from the Pulmonary Fibrosis Foundation Registry and Duke University Health System show no significant difference in disease progression risk between patients on full dose antifibrotics and those who reduce or stop therapy.
3. Disease progression rates remain high despite antifibrotic use, emphasizing the urgent need for more effective and better-tolerated treatment options.
